Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics (CAPR – Research Report) yesterday and set a price target of $12.00. The company’s shares opened today at $4.56.
McCarthy covers the Healthcare sector, focusing on stocks such as BioNano Genomics, Lineage Therap, and Achieve Life Sciences. According to TipRanks, McCarthy has an average return of -34.7% and a 14.63% success rate on recommended stocks.
Capricor Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $15.00, representing a 228.95% upside. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $6.58 and a one-year low of $2.81. Currently, Capricor Therapeutics has an average volume of 104.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.
Read More on CAPR:
- Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15
- Capricor Therapeutics Receives Clinical Research Forum’s 2023 Top Ten Clinical Research Achievement Award
- Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan
- Capricor, Nippon Shinyaku enter commercialization, distribution partnership
